NCT01881386 is a clinical trial of Magnetic Resonance Imaging (MRI) in Cancer, sponsored by Institute of Cancer Research, United Kingdom.

Who is sponsoring NCT01881386?

NCT01881386 is sponsored by Institute of Cancer Research, United Kingdom.

What drugs are being tested in NCT01881386?

Interventions in NCT01881386: Magnetic Resonance Imaging (MRI).

Is NCT01881386 still recruiting?

NCT01881386 is currently completed. Last updated 28 January 2020.

Last reviewed 2020-01-28 · How we verify

NCT01881386

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lactate Imaging as a Tumour Biomarker

Completed Last updated 28 January 2020

What this trial tests

trial testing Magnetic Resonance Imaging (MRI) in Cancer in 37 participants. Completed in 1 September 2017.

Timeline

1 September 2013

Primary endpoint
1 September 2017

1 September 2017

Quick facts

Lead sponsor	Institute of Cancer Research, United Kingdom
Status	Completed
Study type	OBSERVATIONAL
Enrollment	37
Start date	1 September 2013
Primary completion	1 September 2017
Estimated completion	1 September 2017
Sites	1 location across United Kingdom

Drugs / interventions tested

Magnetic Resonance Imaging (MRI)

Conditions studied

Cancer — all drugs for Cancer →

Sponsor

Institute of Cancer Research, United Kingdom

Who can join

Adults 18 to 80, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project is designed to investigate whether measurements of lactate in tumours, made using a magnetic resonance technique similar to MRI, is an effective non-invasive method to detect whether some new targeted drugs are having their desired effect. The study hypothesis is that by using magnetic resonance spectroscopy techniques, we will be able to observe changes in tumour lactate levels in vivo, in response to treatment.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Lactate metabolism in human health and disease.
Li X, Yang Y, Zhang B, Lin X, et al · · 2022 · cited 928× · PMID 36050306 · DOI 10.1038/s41392-022-01151-3
Crosstalk between lactate and tumor-associated immune cells: clinical relevance and insight.
Sun K, Shen Y, Xiao X, Xu H, et al · · 2024 · cited 10× · PMID 39678492 · DOI 10.3389/fonc.2024.1506849
Lactate at the crossroads of tumor metabolism and immune escape: a new frontier in cancer therapy.
Dong Z, Yuan Z, Jin T, Gao C, et al · · 2025 · cited 6× · PMID 41204256 · DOI 10.1186/s12967-025-07272-x

Verify or expand the search:

Other trials of Magnetic Resonance Imaging (MRI)

Trials testing the same drug.

NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting
NCT07346170 — Short Interval Postoperative Stereotactic Body Radiation Therapy (SBRT) After Surgical Intervention for Spine Metastases · NA · not yet recruiting
NCT07110246 — Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas · Phase 2 · recruiting
NCT07185958 — Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy · not yet recruiting
NCT06492057 — Electromyostimulation (EMS) of Astronauts in Spaceflight (Easymotion-2) · NA · enrolling by invitation

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other Institute of Cancer Research, United Kingdom trials

Trials by the same sponsor.

NCT06396754 — Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC · not yet recruiting
NCT07391215 — 5G-PEARL: Paxalisib in Malignant Brain Tumours · Phase 1, PHASE2 · recruiting
NCT07098819 — The eValuation of Sources of vIBRAtioN for Vibrational Shear Wave elasTography · not yet recruiting
NCT06636526 — The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study). · recruiting
NCT06630260 — 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01881386 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Cancer Research, United Kingdom
Last refreshed: 28 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01881386.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing